Cue Biopharma Inc. (NASDAQ: CUE)
$0.93
+0.0020 ( +0.21% ) 279.9K
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
Market Data
Open
$0.93
Previous close
$0.93
Volume
279.9K
Market cap
$45.34M
Day range
$0.90 - $0.97
52 week range
$0.85 - $4.89
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
ars | Annual reports | 1 | Apr 26, 2024 |
10-k | Annual reports | 103 | Mar 28, 2024 |
4 | Insider transactions | 1 | Mar 08, 2024 |
4 | Insider transactions | 1 | Mar 08, 2024 |
4 | Insider transactions | 1 | Mar 08, 2024 |
4 | Insider transactions | 1 | Mar 08, 2024 |
4 | Insider transactions | 1 | Mar 08, 2024 |
4 | Insider transactions | 1 | Feb 22, 2024 |
4 | Insider transactions | 1 | Jan 04, 2024 |
4 | Insider transactions | 1 | Jan 04, 2024 |